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Summary
Objective: High-sensitivity C-reactive protein (hsCRP) in serum is used as a marker of risk for cardiovascular disease (CVD); however CRP is
a non-speciﬁc acute phase reactant. We evaluated the association between hsCRP concentrations and the most common form of arthritis,
osteoarthritis (OA), and assessed the applicability of hsCRP for CVD risk prediction.
Methods: Participants (n¼ 662) were selected from the population-based Johnston County Osteoarthritis Project, using stratiﬁed simple ran-
dom sampling to achieve balance according to radiographic knee OA status, ethnic group, gender, and age group. The presence and severity
of knee and hip OA were determined radiographically. CVD risk was estimated by hsCRP concentration and independently with the Framing-
ham risk algorithm.
Results: Serum natural log-transformed hsCRP (ln hsCRP) was higher in African-Americans (P< 0.0001) and women (P< 0.0001), was
higher in participants who had chronic pulmonary disease (P¼ 0.01), hypertension (P< 0.0001), or used pain medications (P¼ 0.004),
and correlated with body mass index (BMI) (r¼ 0.40, P< 0.0001) and waist circumference (r¼ 0.33, P< 0.0001), but not with age, CVD,
or current smoking. Ln hsCRP was strongly positively associated with all deﬁnitions of radiographic OA (rOA; P< 0.0001), but this association
was not independent of BMI. Although 183 participants reported no CVD and were classiﬁed as low risk by the Framingham CVD score, 61%
of them were classiﬁed as moderate or high risk for CVD using hsCRP; this proportion designated high risk for CVD on the basis of hsCRP
consisted primarily of women (P< 0.05) and individuals with OA (P< 0.01).
Conclusions: The pathogenic signiﬁcance of hsCRP elevations in this subgroup is unclear. Serum hsCRP for predicting risk of CVD is con-
founded by obesity, ethnicity, gender and comorbidities.
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SocietyBackground
The development of robust assays of superior sensitivity
compared to those for basic C-reactive protein (CRP) mea-
surement has allowed for the distinction of patients who
have low levels of inﬂammation. These high-sensitivity
CRP (hsCRP) assays have led to increasing use of this pro-
tein in the study of the inﬂammatory nature of many chronic
diseases including atherosclerosis1,2 and OA3. Although
CRP has been evaluated in the setting of OA for almost two
decades, it was not until the advent of the high-sensitivity
assays that associations with the disease were recognized.
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OA4,5, and are associated with OA severity6 and joint pain7,
as well as incident and progressive disease8e11. None of
these studies has looked extensively at the impact of
comorbidities on hsCRP in a population-based study, nor
have any of these studies evaluated the impact of OA on
the use of hsCRP for cardiovascular disease (CVD) risk
assessment. This prompted us to evaluate the current pub-
lished American Heart Association and Centers for Disease
Control and Prevention (AHA/CDC) guidelines for estimat-
ing CVD risk based upon hsCRP concentrations, and the
possible confounding of these guidelines by the presence
of OA and other comorbidities, in an ethnically diverse, pop-
ulation derived sample.
Materials and methods
SUBJECTS
Participants for this Johnston County OA Project Bio-
marker Sub-study were selected from individuals in the
baseline examination of the Johnston County Osteoarthritis
Project, a population-based study of OA in rural North
Carolina12 and included males and females aged 45 years6
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ascertained by self-report. From the 3187 participants, 388
African-Americans and 820 Caucasians had an available
serum sample drawn at the time of radiography plus either
KellgreneLawrence (KeL) grade 0 in both knees and both
hips (radiographic OA [rOA] unaffected) or KeL grade 2
in at least one knee (radiographic knee OA affected). Of
these participants, we selected all 388 African-Americans
and randomly selected 394 Caucasians, in approximately
equal numbers from the 12 cells obtained from the cross-
classiﬁcation of sex, age group (ages 45e54 years,
55e64 years, 65 years), and OA status (affected/unaf-
fected). Selection was independent of knee symptoms.
The presence of 14 self-reported, current, physician-,
nurse-, or health professional-diagnosed co-morbid condi-
tions was assessed with an interviewer-administered ques-
tionnaire in a format similar to that used by the National
Health Interview Survey13. These current conditions
included chronic pulmonary disease (asthma, chronic bron-
chitis, or emphysema), CVD (heart attack, angina, conges-
tive heart failure, coronary heart disease, other ‘heart
condition’, stroke, or circulation problems), high blood pres-
sure, chronic gallbladder or liver trouble, kidney, prostate or
bladder trouble, diabetes or high blood sugar, insulin use,
gout, rheumatoid arthritis, and cancer. We also ascertained
information on the use of pain medications, current smoking
status, and current hormone replacement therapy use (the
last in women only). Participants with self-reported cancer,
rheumatoid arthritis, and gout were excluded. After these
exclusions, the sample numbered 662. Clinical measures
included height (cm), weight (kg) measured with a balance
beam scale to calculate body mass index (BMI in kg/m2),
and waist circumference (cm) measured at the level of the
umbilicus. Blood pressure was measured three times in
the right arm in the sitting position and the average of the
second and third measurements used in the analyses.
The Institutional Review Boards of the clinical site, the
University of North Carolina at Chapel Hill, and the CDC,
approved all procedures.
RADIOGRAPHIC MEASUREMENTS
Bilateral anteroposterior weight-bearing radiographs of
the knees were performed on all participants. Anteroposte-
rior supine pelvis radiographs were obtained on women 50
years of age or older and all men. A single musculoskeletal
radiologist (JBR) scored all radiographs for KeL radio-
graphic grade14 as described previously12. Non-OA controls
were deﬁned as KeL grade 0 in both knees and both hips;
an OA case was deﬁned as KeL grade 2 in at least one
knee. rOA outcomes included knee OA (present or absent);
knee OA laterality (none, unilateral or bilateral); knee OA
severity (grade 0, 2, 3 or 4); concomitant knee and hip
OA (none, knee only or present in knee and hip); and num-
ber of large joints with OA (0e4).
hsCRP MEASUREMENTS
Serum samples were stored at 80C prior to assay. Se-
rum hsCRP concentrations were measured using the UBI
Magiwel Enzyme Immunoassay (United Biotech Inc., Moun-
tain View, CA) as per the manufacturer’s instructions and
blinded to the clinical information. The assay is reported to
have a minimum detectable concentration of 0.00035 mg/L.
At a concentration of 0.003 mg/L, our inter-assay precision
was 7.4% (n¼ 20).CHOLESTEROL MEASUREMENTS
Total serum cholesterol was measured enzymatically
using cholesterol/HP reagent (Roche Diagnostics, Indian-
apolis, IN). High-density lipoprotein (HDL) was measured
enzymatically using the ‘‘L-Type HDL-C’’ reagent kit
(Wako, Richmond, VA) adapted to a microplate format as
per the manufacturer’s instructions. The manufacturer’s re-
ported variability for this kit is 0.6e1.15% (intra-assay) and
0.59e2.8% (inter-assay). As with hsCRP, total cholesterol
and HDL measurements were made blinded to the clinical
information.
FRAMINGHAM RISK SCORE FOR CVD
The 10-year risk for CVD was computed for the partici-
pants without self-reported CVD (n¼ 521) using the Fra-
mingham CVD risk prediction algorithm based upon the
seven parameters of gender, age, total cholesterol, HDL
cholesterol, systolic and diastolic blood pressure, smoking
status and diabetes15. Participants were categorized as
low (<10%), moderate (10e20%), or high risk (>20%) for
future CVD based upon the Adult Treatment Panel III guide-
lines of the National Cholesterol Education Program16.
STATISTICAL ANALYSIS
All statistical analyses were performed using SAS 8.2
software (SAS, Cary, NC). In order to satisfy the assump-
tions underlying the use of the statistical models, all analy-
ses were done using natural log-transformed hsCRP (ln
hsCRP) data. The Pearson correlation coefﬁcients were de-
termined for the relationship among ln hsCRP, age, BMI,
and waist circumference. Analysis of covariance was used
to assess differences in means of serum ln hsCRP concen-
trations between groups corresponding to ethnicity, gender,
the presence and absence of self-reported chronic pulmo-
nary disease, CVD, hypertension, use of pain medications,
smoking, diabetes, and insulin dependence. Analysis of co-
variance was also used to assess differences in means of
serum ln hsCRP concentrations between groups corre-
sponding to each deﬁnition of rOA, while adjusting for
age, ethnicity, gender, obesity (BMI or waist circumference),
use of medications for arthritis pain, and selected self-
reported co-morbid medical conditions associated with ln
hsCRP in bivariate analyses.
For participants without self-reported CVD, we calculated
the proportion within each of three CVD risk categories
based upon hsCRP and established by a workshop spon-
sored by the AHA/CDC (<1 mg/L low risk group, 1e3 mg/L
average risk group, and >3 mg/L high risk group)17. Chi-
square analysis was used to evaluate the proportions of
participants who were low risk by Framingham scores but
moderate or high risk by hsCRP concentrations, comparing
OA and non-OA participants, and female and male partici-
pants. Female users of hormone replacement therapy
were excluded for some analyses. A P value <0.05 was
considered signiﬁcant.
Results
hsCRP, OA AND COMORBIDITIES
The sample consisted of 662 individuals, 48% African-
Americans, 58% females, overall mean age (SD) of 61.4
(10.3) years, and mean BMI (SD) 30.0 (6.9) kg/m2. Table I
provides additional descriptive information for OA unaffected
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between ln hsCRP and all deﬁnitions of rOA (Table II). Addi-
tionally, the concentrationsof ln hsCRP tended to increaseon
averagewith each successive joint involvedwithOAandwith
each successive increase in KeL grade of knee OA severity.
An increase of one KeL grade of knee OA resulted in an av-
erage increase of 1.10 mg/L hsCRP (range 0.54e1.54 mg/L
change in hsCRP per KeL grade over the range of KeL
grades 0e4).
Table I
Demographics and clinical characteristics of the study participants
OA unaffected*
(n¼ 276)
OA affected**
(n¼ 386)
Age (years) (SD) 59.9 (9.2) 62.4 (10.9)
BMI (kg/m2) (SD) 27.4 (4.60) 31.9 (7.59)
Female (%) 50 63.7
African-American (%) 34.4 61.1
Chronic pulmonary
disease (%)
11.3 8.9
CVD (%) 22.1 20.7
Hypertension (%) 33.1 42.0
Use of pain
medication (%)
28.5 42.2
Smoking (%) 28.1 12.8
Diabetes (%) 11.2 14.8
Insulin use (%) 5.4 7.0
hsCRP mean (SD) (mg/L) 3.38 (4.89) 5.88 (8.57)
hsCRP median (mg/L) 1.69 3.07
*OA unaffected¼KeL radiographic grade 0 in both knees and
both hips.
**OA affected¼KeL radiographic grade at least 2 in one or both
knees.A moderate correlation was observed between ln hsCRP
and BMI (r¼ 0.40, P< 0.0001), and waist circumference
(r¼ 0.33, P< 0.0001), but not with age (r¼ 0.01, P¼ 0.75).
Mean ln hsCRP was higher in African-Americans compared
to Caucasians (P< 0.0001) and higher in women compared
to men (P< 0.0001) (Table III). The highest hsCRP concen-
trations were observed among African-American women
who had OA. In addition to OA, other conditions that might
have affected hsCRP concentrations included chronic pul-
monary disease, CVD, hypertension, use of painmedication,
current smoking, and diabetes, or insulin use. We found
higher mean ln hsCRP concentrations in participants who
had chronic pulmonary disease (P¼ 0.01), hypertension
(P< 0.0001), or used pain medications (P¼ 0.004), how-
ever, concentrations were not signiﬁcantly different on the
basis of a self-report of CVD (P¼ 0.36) or current smoking
(P¼ 0.16) (Table III).
The associations of ln hsCRP with OA variables were
greatly diminished after adjustment for age, ethnicity, gender,
use of pain medications, chronic pulmonary disease, hyper-
tension, diabetes, and waist circumference (P¼ 0.07).
When adjusted for the other covariates, ln hsCRP was inde-
pendently associated only with BMI (P< 0.0001), ethnicity
(P¼ 0.009), and chronic pulmonary disease (P¼ 0.007).
hsCRP AND CVD RISK ASSESSMENT
We calculated the Framingham risk score for the 521 par-
ticipants without self-reported CVD (absence of heart
attack, angina, congestive heart failure, coronary heart dis-
ease, other ‘heart condition’, stroke, or circulation problems)
(Table IV). Of these 521 participants without self-
reported CVD, 183 were classiﬁed as low risk by the
Framingham CVD score; however, 61% of them wereTable II
LnCRP by rOA affection status
Group n Mean
hsCRP
(mg/L)
Mean
Ln
hsCRP
95%
Conﬁdence
intervals
Presence of knee rOA
KeL knee 0/KeL hip 0 276 1.60 7.38 7.22e7.54
KeL knee 2e4 386 2.56 7.85** 7.72e7.99
Knee rOA severity
KeL knee 0/KeL hip 0 276 1.60 7.38 7.22e7.54
KeL knee 2 264 2.16 7.68* 7.52e7.84
KeL knee 3 88 3.32 8.11** 7.82e8.39
KeL knee 4 34 4.92 8.50** 8.05e8.96
Laterality of knee rOA
KeL knee 0/KeL hip 0 276 1.60 7.38 7.22e7.54
Unilateral KeL knee 2e4 192 2.07 7.64* 7.45e7.83
Bilateral KeL knee 2e4 194 3.16 8.06** 7.87e8.25
Co-occurrence of knee and hip rOA
KeL knee 0/KeL hip 0 276 1.60 7.38 7.22e7.54
KeL knee 2e4/KeL hip 0 218 2.27 7.73* 7.55e7.91
KeL knee 2e4/KeL hip 2e4 122 2.60 7.87* 7.62e8.11
Numbers of knees and hips with rOA
0 Joints affected 276 1.60 7.38 7.22e7.54
1 Joint affected 115 1.75 7.47 7.22e7.72
2 Joints affected 132 2.78 7.93** 7.70e8.16
3 Joints affected 51 2.48 7.82* 7.45e8.19
4 Joints affected 42 3.29 8.10* 7.69e8.51
For presentation purposes in this Table hsCRP was expressed in mg/L prior to natural log transformation. *P< 0.05 compared to control;
**P< 0.0001 compared to control. rOA¼KeL grades 2e4.
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Ln hsCRP and demographics and clinical characteristics
Mean
hsCRP (mg/L)
Mean Ln
hsCRPx
95%
Conﬁdence intervals
of Ln hsCRP
Race** Caucasian 1.63 7.40 7.25e7.54
African-American 2.76 7.93 7.78e8.07
Gender** Male 1.65 7.41 7.25e7.57
Female 2.51 7.83 7.69e7.97
Chronic pulmonary disease* No 2.01 7.61 7.50e7.72
Yes 3.19 8.07 7.73e8.40
CVD No 2.03 7.62 7.50e7.74
Yes 2.37 7.77 7.54e8.00
Hypertension** No 1.77 7.48 7.35e7.61
Yes 2.80 7.94 7.77e8.11
Use of pain medication* No 1.86 7.53 7.40e7.66
Yes 2.64 7.88 7.71e8.05
Smoking No 2.18 7.69 7.57e7.81
Yes 1.76 7.47 7.23e7.71
Diabetes** No 1.94 7.57 7.46e7.68
Yes 3.64 8.20 7.92e8.49
Insulin use* No 2.02 7.61 7.50e7.72
Yes 3.86 8.26 7.84e8.68
xFor presentation purposes, hsCRP was expressed in mg/L prior to natural log transformation. *P< 0.05 compared to referent; **P< 0.0001
compared to referent.classiﬁed as moderate or high risk for CVD using hsCRP.
Of those classiﬁed as low risk by Framingham score but
moderate or high risk by hsCRP concentration, 58% had
OA (P< 0.01 compared to the corresponding proportion
among non-OA participants), and 86% were females
(P< 0.05 compared to the corresponding proportion among
male participants).
Discussion
hsCRP was strongly associated with OA of the knees and
hips. hsCRP was also correlated with waist circumference
and BMI, a strong risk factor for OA and OA progression.
It remains unclear whether the association between hsCRP
and OA is confounded by another factor present in those
patients with obesity. CRP may be associated with obesitysolely, or reﬂect the presence of underlying OA and the
complex interaction of OA and obesity. We believe that
the CRP elevations associated with OA likely reﬂect a com-
plex interaction of fat mass, joint inﬂammation, and sys-
temic inﬂammation, as summarized in Fig. 1. Obesity (fat
mass) is both a mechanical risk factor for OA, capable of in-
ducing localized joint degeneration and inﬂammation, and
a contributor to a systemic proinﬂammatory state that could
further exacerbate joint disease and promote CRP produc-
tion by the liver18,19. Moreover, the inﬂamed joint, in addition
to fat mass, is potentially capable of increasing CRP
synthesis by the liver by means of cytokines of joint tissue
origin. Support for this hypothesis has been provided in a re-
cent study of knee OA20. Serum hsCRP was positively as-
sociated with synovial inﬂammatory inﬁltrates, and synovial
ﬂuid interleukin-6 (IL-6) concentrations correlated with se-
rum hsCRP concentrations. Taken together, these dataTable IV
Cross-classification of participants for CVD risk by both AHA/CDC (hsCRP) criteria and Framingham risk categories for the 521 participants
without self-reported CVD
Framingham risk category
OA unaffected (n, column %) OA affected (n, column %)
Low
(n¼ 90)
Moderate
(n¼ 86)
High
(n¼ 57)
Low
(n¼ 93)
Moderate
(n¼ 119)
High
(n¼ 76)
AHA/CDC
risk
category
Low risk 43 (48%) 36 (42%) 12 (21%) 29 (31%) 30 (25%) 20 (26%)
Moderate risk 20 (22%) 27 (31%) 17 (30%) 21 (23%) 24 (20%) 21 (28%)
High risk 27 (30%) 23 (27%) 28 (49%) 43 (46%) 65 (55%) 35 (46%)
Framingham risk category: 10-year cardiovascular risk category deﬁned as low <10% risk, moderate 10e20% risk, and high >20% risk
based upon Grundy et al16. AHA/CDC risk category: AHA and CDC, CVD risk categories based upon hsCRP and deﬁned as low hsCRP
<1 mg/L, moderate hsCRP 1e3 mg/L, and high hsCRP >3 mg/L risk based upon Pearson et al17.
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OA and hsCRP production and support a complex interac-
tion of factors acting in concert to promote CRP production.
We found a strong independent association of hsCRP
and ethnicity, in agreement with a recent report that median
hsCRP concentration was 30% higher in blacks than in
whites in Dallas County, characterized as a typical multieth-
nic US urban population21. Occult infection, such as peri-
odontal disease, has also been found to be associated
with elevated hsCRP concentrations in otherwise healthy
individuals22. Taken together with the strong independent
association of hsCRP with chronic pulmonary disease,
and association with BMI, serum CRP is unlikely to be use-
ful as a single biomarker of OA or, as described below,
of CVD.
Surprisingly, we did not ﬁnd an association of hsCRP with
smoking or with self-reported CVD. However, these results
are also in agreement with the large population-based
Dallas Heart study of 3373 individuals, aged 30e65 years
that found no association of hsCRP with smoking and also
no independent association of hsCRP with atherosclerotic
burden deﬁned by either coronary artery calciﬁcation on
cardiac electron-beam computed tomography scans or by
abdominal aortic plaque on magnetic resonance images23.
In our study, CVD risk was estimated by hsCRP and inde-
pendently, using the Framingham risk algorithm, for the
subgroup without CVD by self-report. The Framingham
risk algorithm was based upon the population of Framing-
ham, MA, but has been validated subsequently in diverse
populations in the US15,24. These two methods of CVD
risk assessment were incongruent, with greater CVD risk
levels attributed, on the basis of hsCRP, to women (even
after excluding hormone replacement users [data not
shown]) and participants with OA. The CDC has estimated
that one in three US adults has arthritis and joint symp-
toms25, among them OA, which accounts for the majority of
cases of arthritis. Although it is recommended that hsCRP
testing should be performed in a ‘‘metabolically stable
person without obvious inﬂammatory or infectious condi-
tions’’ and without a systemic inﬂammatory process17, tradi-
tionally, individuals with OA would not be considered to
have a metabolic or systemic inﬂammatory disease, and
therefore, would not be exempt from testing by these crite-
ria. Individuals who are obese with arthritis may therefore
contribute substantially to the recently reported phenome-
non that half of US adults have hsCRP levels greater than
2 mg/L26. Thus, the Framingham risk score would appear
Fig. 1. OA and obesity interact to promote CRP production. In this
model, both fat mass and the inﬂamed joint contribute to CRP in-
duction by the liver. It is controversial whether CRP in turn, at
high levels, may promote a proinﬂammatory state [see Pepys
et al 28 and Bisoendial et al 29].to be a preferred method of assessing CVD risk in an OA
patient based on our data, and the report by Wilson
et al.27 that hsCRP does not add prognostic information
for predicting future major CVD beyond the traditional
‘‘ofﬁce risk assessment’’ provided by the Framingham risk
score.
Conclusions
Ethnicity, chronic pulmonary disease, and obesity exert
strong inﬂuences on serum hsCRP concentration and con-
found the prediction of CVD risk based upon hsCRP. This is
particularly problematic for individuals with OA in whom
obesity is prevalent, and whose disease state may provide
a proinﬂammatory stimulus, difﬁcult or impossible to sepa-
rate from obesity.
Acknowledgments
We dedicate this manuscript to the memory of our friend
and colleague Dr Frederick Cobb, who provided encour-
agement and suggestions during the preparation of this
manuscript. We also wish to thank Dr William Kraus, mem-
ber of the Division of Cardiology, and Dr David Pisetsky,
Chief, Division of Rheumatology, at Duke University Medi-
cal Center, for manuscript suggestions and editing. We
thank Dr Catherine Hammett-Stabler, Director of Clinical
Toxicology and Pharmacology Laboratories at the Univer-
sity of North Carolina at Chapel Hill, for providing expert
technical advice regarding hsCRP and editorial sugges-
tions. We thank Erik Myers, at the University of North
Carolina at Chapel Hill, for help related to database
management.
References
1. Ridker PM. High-sensitivity C-reactive protein, inﬂam-
mation, and cardiovascular risk: from concept to clini-
cal practice to clinical beneﬁt. Am Heart J Jul 2004;
148(1 Suppl):S19e26.
2. Armani A, Becker RC. The biology, utilization, and at-
tenuation of C-reactive protein in cardiovascular dis-
ease: part II. Am Heart J Jun 2005;149(6):977e83.
3. Sipe JD. Acute-phase proteins in osteoarthritis. Semin
Arthritis Rheum 1995;25(2):75e86.
4. Conrozier T, Carlier MC, Mathieu P, Colson F,
Debard AL, Richard S, et al. Serum levels of YKL-40
and C reactive protein in patients with hip osteoarthritis
and healthy subjects: a cross sectional study. Ann
Rheum Dis 2000;59(10):828e31.
5. Sharif M, Elson CJ, Dieppe PA, Kirwan JR. Elevated
serum C-reactive protein levels in osteoarthritis. Br J
Rheumatol 1997;36(1):140e1.
6. Wolfe F. The C-reactive protein but not erythrocyte sed-
imentation rate is associated with clinical severity in
patients with osteoarthritis of the knee or hip. J Rheu-
matol 1997;24(8):1486e8.
7. Sturmer T, Brenner H, Koenig W, Gunther KP. Severity
and extent of osteoarthritis and low grade systemic
inﬂammation as assessed by high sensitivity C reac-
tive protein. Ann Rheum Dis 2004;63(2):200e5.
8. Conrozier T, Chappuis-Cellier C, Richard M, Mathieu P,
Richard S, Vignon E. Increased serum C-reactive pro-
tein levels by immunonephelometry in patients with
971Osteoarthritis and Cartilage Vol. 15, No. 8rapidly destructive hip osteoarthritis. Rev Rhum Engl
Ed 1998;65(12):759e65.
9. Sharif M, Shepstone L, Elson CJ, Dieppe PA,
Kirwan JR. Increased serum C reactive protein may
reﬂect events that precede radiographic progression
in osteoarthritis of the knee. Ann Rheum Dis 2000;
59(1):71e4.
10. Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N,
Gallimore JR, et al. Low-level increases in serum
C-reactive protein are present in early osteoarthritis
of the knee and predict progressive disease. Arthritis
Rheum 1997;40(4):723e7.
11. Sowers M, Jannausch M, Stein E, Jamadar D,
Hochberg M, Lachance L. C-reactive protein as a bio-
marker of emergent osteoarthritis. Osteoarthritis Carti-
lage 2002;10(8):595e601.
12. Jordan JM, Linder GF, Renner JB, Fryer JG. The im-
pact of arthritis in rural populations. Arthritis Care
Res 1995;8(4):242e50.
13. Statistics NCfH. NHIS survey description document,
http://www.cdc.gov/nchs/nhis.htm; 1995 (Accessed
January 24, 2005).
14. Kellgren J, Lawrence J. Radiological assessment of
osteoarthrosis. Ann Rheum Dis 1957;16:494e502.
15. Wilson PW, D’Agostino RB, Levy D, Belanger AM,
Silbershatz H, Kannel WB. Prediction of coronary
heart disease using risk factor categories. Circulation
1998;97(18):1837e47.
16. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr,
Clark LT, Hunninghake DB, et al. Implications of re-
cent clinical trials for the National Cholesterol Educa-
tion Program Adult Treatment Panel III guidelines
(erratum appears in Circulation Aug 10, 2004;110(6):
763). Circulation 2004;110(2):227e39.
17. Pearson TA, Mensah GA, Alexander RW, Anderson JL,
Cannon RO 3rd, Criqui M, et al. Markers of inﬂamma-
tion and cardiovascular disease: application to clinical
and public health practice: a statement for healthcare
professionals from the Centers for Disease Control
and Prevention and the American Heart Association.
Circulation Jan 28, 2003;107(3):499e511.
18. Grifﬁn TM, Guilak F. The role of mechanical loading in
the onset and progression of osteoarthritis. Exerc
Sport Sci Rev Oct 2005;33(4):195e200.
19. Guilak F, Fermor B, Keefe FJ, Kraus VB, Olson SA,
Pisetsky DS, et al. The role of biomechanics andinﬂammation in cartilage injury and repair. Clin Orthop
Jun 2004;423:17e26.
20. Pearle A, Scanzello C, DiCarlo E, Mandl L, Crow M,
Sculco T. Elevated CRP levels in osteoarthritis are
associated with local inﬂammation. Trans Orthop Res
2005;30:1412.
21. Khera A, McGuire DK, Murphy SA, Stanek HG,
Das SR, Vongpatanasin W, et al. Race and gender dif-
ferences in C-reactive protein levels. J Am Coll Cardiol
Aug 2, 2005;46(3):464e9.
22. Slade GD, Ghezzi EM, Heiss G, Beck JD, Riche E,
Offenbacher S. Relationship between periodontal
disease and C-reactive protein among adults in the
Atherosclerosis Risk in Communities study. Arch
Intern Med May 26, 2003;163(10):1172e9.
23. Khera A, de Lemos JA, Peshock RM, Lo HS,
Stanek HG, Murphy SA, et al. Relationship between
C-reactive protein and subclinical atherosclerosis:
the Dallas Heart Study. Circulation Jan 3, 2006;
113(1):38e43.
24. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P.
Validation of the Framingham coronary heart disease
prediction scores: results of a multiple ethnic groups
investigation. JAMA Jul 11, 2001;286(2):180e7.
25. Centers for Disease Control. Prevalence of self-reported
arthritis or chronic joint symptoms among adults e
United States, 2001. MMWR 2002;51(42):948e50.
26. Woloshin S, Schwartz LM. Distribution of C-reactive
protein values in the United States. N Engl J Med
2005;352(15):1611e3.
27. Wilson PW, Nam BH, Pencina M, D’Agostino RB Sr,
Benjamin EJ, O’Donnell CJ. C-reactive protein and
risk of cardiovascular disease in men and women
from the Framingham Heart Study. Arch Intern Med
Nov 28, 2005;165(21):2473e8.
28. Pepys MB, Hawkins PN, Kahan MC, Tennent GA,
Gallimore JR, Graham D, et al. Proinﬂammatory effects
of bacterial recombinant human C-reactive protein are
caused by contamination with bacterial products, not
by C-reactive protein itself. Circ Res Nov 25, 2005;
97(11):e97ee103.
29. Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ,
van den Bogaard B, Reitsma PH, et al. Activation
of inﬂammation and coagulation after infusion of
C-reactive protein in humans. Circ Res Apr 15,
2005;96(7):714e6.
